Ani Pharmaceuticals (ANIP) Other Operating Expenses (2010 - 2026)

Ani Pharmaceuticals has disclosed Other Operating Expenses across 17 years of filings, most recently posting $114.3 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $114.3 million, up 36.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $213.1 million (up 36.09% YoY), and the FY2025 annual result was -$382000.0, down 107.14% from the prior year.
• Other Operating Expenses came in at $114.3 million for Q1 2026 at Ani Pharmaceuticals, up from -$87000.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $114.3 million in Q1 2026 to a low of -$295000.0 in Q3 2025.
• The 5-year median for Other Operating Expenses is $58.6 million (2024), against an average of $59.1 million.
• Across the five-year window, Other Operating Expenses jumped 672.32% in 2022 and grew 7.64% in 2023, its largest moves.
• Ani Pharmaceuticals' Other Operating Expenses stood at $48.1 million in 2022, then jumped by 46.85% to $70.6 million in 2023, then climbed by 3.05% to $72.8 million in 2024, then plunged by 100.12% to -$87000.0 in 2025, then soared by 131501.15% to $114.3 million in 2026.
• The last three Other Operating Expenses figures came in at $114.3 million (Q1 2026), -$87000.0 (Q4 2025), and -$295000.0 (Q3 2025), per Business Quant data.